|February 23, 2018 2:04 p.m.|
Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio to Present Iclaprim Data at ECCMID 2018|
February 21, 2018
|Appointment of Jonathan E. Gold as Interim Chief Financial Officer|
February 2, 2018
|Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group|
January 29, 2018